Capital Markets Day: Commercial Execution and Innovation in Obesity Care
20
Commercial execution and innovation
Obesity care
The CagriSema phase 3 programme, REDEFINE, is expected to
begin in second half of 2022
N = 2500
REDEFINE 1 trial design
CagriSema 2.4 mg/2.4 mg1
Cagrilintide 2.4 mg1
Semaglutide 2.4 mg¹
Placebo¹
N=800
REDEFINE 2 trial design
CagriSema 2.4 mg/2.4 mg1
Placebo¹
Week
0
16
68
75
Dose
escalation
Treatment
maintenance
Follow-
up
Inclusion criteria
Primary endpoints:
ㅏ
+
Week
0
16
Dose
escalation
Novo NordiskⓇ
+
68
75
Treatment
Follow-
up
maintenance
Confirmatory secondary endpoints:
Change in waist circumference
REDEFINE 1:
•
Change in body weight (%)
.
BMI: ≥ 30 kg/m² or ≥ 27 kg/m² and ≥1 comorbidity
Excludes diabetes diagnosis or HbA1c > 6.5%
•
Achieve ≥ 5% body weight reduction
.
HbA1c
•
Systolic blood pressure
REDEFINE 2:
BMI: ≥ 27 kg/m²
Type 2 diabetes, HbA1c <10%
Patient reported outcomes²
'As an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight. 2 Patient reported outcomes include (IWQOL-Lite-CT, SF-36v2, and Vitality score)
CagriSema: Cagrilintide in combination with semaglutide; T2DM: Type 2 diabetes; BMI: Body mass index; HbA1c: Hemoglobin A₁; IWQOL-Lite-CT: Impact of weight on quality of life - lite, clinical trials version; Short form 36v2
CMD22
CAPITAL MARKETS DAYView entire presentation